point-counterpoint q&a w/ dr. lin: oncotype dx genomic prostate score in active surveillance
Published 4 years ago • 546 plays • Length 16:11Download video MP4
Download video MP3
Similar videos
-
17:45
point-counterpoint: oncotype dx genomic prostate score in active surveillance – canary pass study
-
8:07
point-counterpoint q&a w/ dr. klein: oncotype dx genomic prostate score in active surveillance
-
8:43
industry perspective: the oncotype dx genomic prostate score assay test
-
9:15
point-counterpoint: active surveillance for intermediate-risk prostate cancer - pro
-
1:45
dr. febbo explains the oncotype dx genomic prostate score
-
9:59
point-counterpoint: active surveillance for intermediate-risk prostate cancer - con
-
9:40
standard treatments and global perspective 1080p
-
9:25
gleason 3 4 active surveillance, psma alternatives, and more | answering youtube comments #46 | pcri
-
13:47
49: active surveillance for low-risk prostate cancer with laurence klotz, m.d.
-
2:25
dr. katz on the oncotype dx gps assay in prostate cancer
-
28:33
active surveillance results and implications of prospective studies
-
12:19
active surveillance 2022: who qualifies, who does not and how should it be monitored
-
23:37
active surveillance who is the right patient and what is the right protocol
-
25:24
active surveillance in 2021 part 2: imaging and biomarkers
-
6:09
germline testing for prostate cancer active surveillance
-
11:36
point-counterpoint: will conventional imaging become obsolete? – con
-
1:58
integrated diagnostics and patient selection for active surveillance and treatment
-
5:15
point-counterpoint: will conventional imaging become obsolete?–pro
-
40:42
global grand rounds: active surveillance for prostate cancer with matthew e. nielsen, md,ms,facs
-
14:13
point-counterpoint: muscle invasive bladder cancer–trimodal therapy perspective
-
20:48
point-counterpoint: management of mcrpc